Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Extracapsular Lymph Node Involvement in Ovarian Carcinoma.

Heublein S, Schulz H, Marmé F, Angele M, Czogalla B, Burges A, Mahner S, Mayr D, Jeschke U, Schmoeckel E.

Cancers (Basel). 2019 Jul 1;11(7). pii: E924. doi: 10.3390/cancers11070924.

2.

Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.

Schmoeckel E, Hofmann S, Fromberger D, Rottmann M, Luthardt B, Burges A, Jeschke U, Kirchner T, Lax SF, Mayr D.

Virchows Arch. 2019 May;474(5):599-608. doi: 10.1007/s00428-019-02528-6. Epub 2019 Feb 7.

PMID:
30734108
3.

Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.

Heublein S, Page S, Mayr D, Schmoeckel E, Trillsch F, Marmé F, Mahner S, Jeschke U, Vattai A.

Int J Mol Sci. 2019 Jan 12;20(2). pii: E295. doi: 10.3390/ijms20020295.

4.

Involvement of ILR4α and TLR4 in miscarriages.

Kolben TM, Rogatsch E, Hester A, Kuhn C, Schmoeckel E, Czogalla B, Mahner S, Jeschke U, Kolben T.

J Reprod Immunol. 2019 Feb;131:36-43. doi: 10.1016/j.jri.2018.12.001. Epub 2019 Jan 8.

PMID:
30639993
5.

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients.

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F.

Int J Mol Sci. 2018 Dec 29;20(1). pii: E112. doi: 10.3390/ijms20010112.

6.

CCL1 is a major regulatory T cell attracting factor in human breast cancer.

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.

BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8.

7.

The role of EP3-receptor expression in cervical dysplasia.

Hester A, Ritzer M, Kuhn C, Schmoeckel E, Mayr D, Kolben T, Dannecker C, Mahner S, Jeschke U, Kolben TM.

J Cancer Res Clin Oncol. 2019 Feb;145(2):313-319. doi: 10.1007/s00432-018-2785-3. Epub 2018 Nov 7.

PMID:
30402741
8.

Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer.

Kahlert S, Kolben TM, Schmoeckel E, Czogalla B, Hester A, Degenhardt T, Kempf C, Mahner S, Harbeck N, Kolben T.

Eur J Surg Oncol. 2018 Sep;44(9):1318-1323. doi: 10.1016/j.ejso.2018.06.014. Epub 2018 Jun 23.

PMID:
30041974
9.

PPARγ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas.

Kolben TM, Rogatsch E, Vattai A, Hester A, Kuhn C, Schmoeckel E, Mahner S, Jeschke U, Kolben T.

Int J Mol Sci. 2018 Jun 26;19(7). pii: E1872. doi: 10.3390/ijms19071872.

10.

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.

Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben TM, Kolben T, Zeder-Goess C, Weis F, Gallwas J, Wuerstlein R, Hermelink K, Schmoeckel E, Harbeck N, Mayr D, Mahner S, Jeschke U, Ditsch N.

BMC Cancer. 2018 Apr 16;18(1):431. doi: 10.1186/s12885-018-4286-9.

11.
12.

The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.

Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D.

PLoS One. 2018 Feb 16;13(2):e0192881. doi: 10.1371/journal.pone.0192881. eCollection 2018.

13.

Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9.

Schulz H, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U, Schmoeckel E.

Int J Mol Sci. 2018 Jan 22;19(1). pii: E323. doi: 10.3390/ijms19010323.

14.

Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.

Kolben T, Jeschke U, Reimer T, Karsten N, Schmoeckel E, Semmlinger A, Mahner S, Harbeck N, Kolben TM.

J Cancer Res Clin Oncol. 2018 Feb;144(2):249-256. doi: 10.1007/s00432-017-2551-y. Epub 2017 Nov 28.

PMID:
29185091
15.

LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.

Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.

Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.

16.

Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.

Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U.

Int J Mol Sci. 2017 Jun 8;18(6). pii: E1230. doi: 10.3390/ijms18061230.

17.

Inhibition of Cdk5 induces cell death of tumor-initiating cells.

Mandl MM, Zhang S, Ulrich M, Schmoeckel E, Mayr D, Vollmar AM, Liebl J.

Br J Cancer. 2017 Mar 28;116(7):912-922. doi: 10.1038/bjc.2017.39. Epub 2017 Feb 21.

18.

Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia.

Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, Schmoeckel E, Mayr D, Sommer NN, Mahner S, Jeschke U.

Future Oncol. 2017 Jan;13(2):145-157. Epub 2016 Sep 20.

PMID:
27646625

Supplemental Content

Loading ...
Support Center